Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00069095
Registration number
NCT00069095
Ethics application status
Date submitted
15/09/2003
Date registered
18/09/2003
Date last updated
6/10/2016
Titles & IDs
Public title
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
Query!
Scientific title
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Query!
Secondary ID [1]
0
0
NO16966
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Colorectal Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Bowel - Back passage (rectum) or large bowel (colon)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Oxaliplatin 130 mg/m^2
Treatment: Drugs - Capecitabine 1000 mg/m^2
Treatment: Drugs - Bevacizumab 7.5 mg/kg
Treatment: Drugs - Placebo for bevacizumab 7.5 mg/kg
Treatment: Drugs - Oxaliplatin 85 mg/m^2
Treatment: Drugs - Leucovorin 200 mg/m^2
Treatment: Drugs - Fluorouracil 400 mg/m^2
Treatment: Drugs - Bevacizumab 5 mg/kg
Treatment: Drugs - Placebo for bevacizumab 5 mg/kg
Experimental: XELOX (oxaliplatin+capecitabine) - Patients in the 2-arm part of the study received oxaliplatin 130 mg/m^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m^2 orally twice a day for the first 2 weeks of every 3 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.
Experimental: XELOX (oxaliplatin+capecitabine) + bevacizumab - Patients in the 4-arm part of the study received oxaliplatin 130 mg/m^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m^2 orally twice a day for the first 2 weeks of every 3 week cycle + bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.
Active Comparator: FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil) - Patients in the 2-arm part of the study received oxaliplatin 85 mg/m^2 intravenously (iv) + leucovorin 200 mg/m^2 iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle.
Active Comparator: FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil) + bevacizumab - Patients in the 4-arm part of the study received oxaliplatin 85 mg/m^2 intravenously (iv) + leucovorin 200 mg/m^2 iv + bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle.
Treatment: Drugs: Oxaliplatin 130 mg/m^2
Oxaliplatin was administered in a 2 h infusion before the first dose of capecitabine.
Treatment: Drugs: Capecitabine 1000 mg/m^2
Capecitabine was taken within 30 min after the end of breakfast and dinner.
Treatment: Drugs: Bevacizumab 7.5 mg/kg
Bevacizumab was administered in a 30 to 90 min infusion.
Treatment: Drugs: Placebo for bevacizumab 7.5 mg/kg
Placebo control for bevacizumab (volume equivalent to 7.5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
Treatment: Drugs: Oxaliplatin 85 mg/m^2
Oxaliplatin 85 mg/m^2 was administered simultaneously with leucovorin in a 2 h infusion.
Treatment: Drugs: Leucovorin 200 mg/m^2
Leucovorin was administered simultaneously with oxaliplatin 85 mg/m^2 in a 2 h infusion.
Treatment: Drugs: Fluorouracil 400 mg/m^2
Treatment: Drugs: Bevacizumab 5 mg/kg
Bevacizumab was administered in a 30 to 90 min infusion.
Treatment: Drugs: Placebo for bevacizumab 5 mg/kg
Placebo control for bevacizumab (volume equivalent to 5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored): Non-inferiority of XELOX Versus FOLFOX-4
Query!
Assessment method [1]
0
0
PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4- containing arms was investigated.
Query!
Timepoint [1]
0
0
Baseline until disease progression or death, approximately 2 years 6 months
Query!
Primary outcome [2]
0
0
PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
Query!
Assessment method [2]
0
0
PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
Query!
Timepoint [2]
0
0
Baseline until disease progression or death, approximately 2 years 6 months
Query!
Secondary outcome [1]
0
0
PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Non-inferiority of XELOX Versus FOLFOX-4
Query!
Assessment method [1]
0
0
PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was analyzed on the basis of the tumor response assessments made by the IRC. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Query!
Timepoint [1]
0
0
Baseline until disease progression or death, approximately 2 years 6 months
Query!
Secondary outcome [2]
0
0
PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
Query!
Assessment method [2]
0
0
PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was analyzed on the basis of the tumor response assessments made by the IRC. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the bevacizumab-containing arms was compared with the placebo-containing arms.
Query!
Timepoint [2]
0
0
Baseline until disease progression or death, approximately 2 years 6 months
Query!
Secondary outcome [3]
0
0
PFS (On-treatment Approach): Non-inferiority of XELOX Versus FOLFOX-4
Query!
Assessment method [3]
0
0
PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. The on-treatment analysis included only tumor assessments and death events that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase. Participants who did not have an event during this interval were censored at the date of the last tumor assessment within this time window, or on day 1 if no tumor assessment was available after baseline. Participants who underwent surgical resection with curative intent without prior progression within 28 days after the last confirmed intake of any study medication in the primary study treatment phase were censored at the date of surgery. The on-treatment approach excluded the possible impact of other treatments that might have been started before disease progression. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Query!
Timepoint [3]
0
0
Baseline until disease progression or death, approximately 2 years 6 months
Query!
Secondary outcome [4]
0
0
PFS (On-treatment Approach): Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
Query!
Assessment method [4]
0
0
PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. The on-treatment analysis included only tumor assessments and death events that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase. Participants who did not have an event during this interval were censored at the date of the last tumor assessment within this time window, or on day 1 if no tumor assessment was available after baseline. Participants who underwent surgical resection with curative intent without prior progression within 28 days after the last confirmed intake of any study medication in the primary study treatment phase were censored at the date of surgery. The on-treatment approach excluded the possible impact of other treatments that might have been started before disease progression. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Query!
Timepoint [4]
0
0
Baseline until disease progression or death, approximately 2 years 6 months
Query!
Secondary outcome [5]
0
0
PFS by General Approach, Participants With Curative Surgery Not Censored: Non-inferiority of XELOX Versus FOLFOX-4
Query!
Assessment method [5]
0
0
PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants who underwent curative surgery after experiencing a sufficient shrinkage of their tumor were not censored at the date of surgery, but any relapse, new occurrence of colorectal cancer, or death was considered as an event. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Query!
Timepoint [5]
0
0
Baseline until disease progression or death, approximately 2 years 6 months
Query!
Secondary outcome [6]
0
0
PFS by General Approach, Participants With Curative Surgery Not Censored: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
Query!
Assessment method [6]
0
0
PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants who underwent curative surgery after experiencing a sufficient shrinkage of their tumor were not censored at the date of surgery, but any relapse, new occurrence of colorectal cancer, or death was considered as an event. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
Query!
Timepoint [6]
0
0
Baseline until disease progression or death, approximately 2 years 6 months
Query!
Secondary outcome [7]
0
0
Overall Survival: Non-inferiority of XELOX Versus FOLFOX-4
Query!
Assessment method [7]
0
0
Overall survival was defined as the time from the date of randomization to the date of death. Participants who were not reported to have died at the time of the clinical cut-off date for the analysis were censored using the date they were last known to be alive. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Query!
Timepoint [7]
0
0
Baseline until disease progression or death, approximately 2 years 6 months
Query!
Secondary outcome [8]
0
0
Overall Survival: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
Query!
Assessment method [8]
0
0
Overall survival was defined as the time from the date of randomization to the date of death. Participants who were not reported to have died at the time of the clinical cut-off date for the analysis were censored using the date they were last known to be alive. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
Query!
Timepoint [8]
0
0
Baseline until disease progression or death, approximately 2 years 6 months
Query!
Secondary outcome [9]
0
0
Best Overall Response (BOR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST): Non-inferiority of XELOX Versus FOLFOX-4
Query!
Assessment method [9]
0
0
According to the RECIST criteria, BOR in an individual participant was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Only tumor assessments as assessed by the investigator and made up to and including 28 days after last intake of study medication in the primary study treatment phase not later than date of first curative surgery were included in these analyses. Responders were defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Query!
Timepoint [9]
0
0
From baseline until disease progression/recurrence, approximately 2 years 6 months
Query!
Secondary outcome [10]
0
0
Best Overall Response (BOR) as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
Query!
Assessment method [10]
0
0
According to the RECIST criteria, BOR in an individual participant was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Only tumor assessments as assessed by the investigator and made up to and including 28 days after last intake of study medication in the primary study treatment phase not later than date of first curative surgery were included in these analyses. Responders were defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
Query!
Timepoint [10]
0
0
From baseline until disease progression/recurrence, approximately 2 years 6 months
Query!
Secondary outcome [11]
0
0
BOR as Assessed by the IRC According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
Query!
Assessment method [11]
0
0
According to the RECIST criteria, the BOR in an individual participant was the best response recorded from the start of the treatment until disease progression/recurrence (taking the smallest measurements recorded since the baseline assessment as a reference for PD). The BOR as assessed by the IRC was determined based on tumor assessments that were made up to and including 28 days after last intake of study medication in the primary study treatment phase. Responders were defined as the percentage of participants with a complete response (CR) or partial response (PR). Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Query!
Timepoint [11]
0
0
From baseline until disease progression/recurrence, approximately 2 years 6 months
Query!
Secondary outcome [12]
0
0
BOR as Assessed by the IRC According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
Query!
Assessment method [12]
0
0
According to the RECIST criteria, the BOR in an individual participant was the best response recorded from the start of the treatment until disease progression/recurrence (taking the smallest measurements recorded since the baseline assessment as a reference for PD). The BOR as assessed by the IRC was determined based on tumor assessments that were made up to and including 28 days after last intake of study medication in the primary study treatment phase. Responders were defined as the percentage of participants with a complete response (CR) or partial response (PR). Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
Query!
Timepoint [12]
0
0
From baseline until disease progression/recurrence, approximately 2 years 6 months
Query!
Secondary outcome [13]
0
0
Time to Treatment Failure (TTF) as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
Query!
Assessment method [13]
0
0
Time to treatment failure was defined as the time from the date of randomization to the date of discontinuation of the primary study treatment phase due to adverse event/intercurrent illness, insufficient therapeutic response, death, failure to return, refusing treatment/being unwilling to cooperate, or withdrawing consent; discontinuation of the post study treatment phase due to adverse event, progressive disease, death, participant refusal/administrative reasons, or withdrawing consent; documented disease progression; or death due to any cause, whichever occurred first. The general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase.The on-treatment approach included only tumor assessments and deaths that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase only.
Query!
Timepoint [13]
0
0
From baseline until disease progression/recurrence, approximately 2 years 6 months
Query!
Secondary outcome [14]
0
0
Time to Treatment Failure as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
Query!
Assessment method [14]
0
0
Time to treatment failure was defined as the time from the date of randomization to the date of discontinuation of the primary study treatment phase due to adverse event/intercurrent illness, insufficient therapeutic response, death, failure to return, refusing treatment/being unwilling to cooperate, or withdrawing consent; discontinuation of the post study treatment phase due to adverse event, progressive disease, death, participant refusal/administrative reasons, or withdrawing consent; documented disease progression; or death due to any cause, whichever occurred first. The general approach included all tumor assessments or deaths that occurred during the primary study treatment phase, the post-study treatment phase, or the follow-up phase. The on-treatment approach included only tumor assessments and deaths that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase only.
Query!
Timepoint [14]
0
0
From baseline until disease progression/recurrence, approximately 2 years 6 months
Query!
Secondary outcome [15]
0
0
Time to Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
Query!
Assessment method [15]
0
0
For participants whose BOR was CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status was recorded first) was met. It was based on tumor assessments made by the investigators according to the RECIST criteria. Results were reported as the number of participants achieving a response in 8 time categories from Week 1 to Week 54. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Query!
Timepoint [15]
0
0
Week 1 to Week 54
Query!
Secondary outcome [16]
0
0
Time to Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
Query!
Assessment method [16]
0
0
For participants whose BOR was CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status was recorded first) was met. It was based on tumor assessments made by the investigators according to the RECIST criteria. Results were reported as the number of participants achieving a response in 8 time categories from Week 1 to Week 54. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
Query!
Timepoint [16]
0
0
Week 1 to Week 54
Query!
Secondary outcome [17]
0
0
Duration of Overall Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
Query!
Assessment method [17]
0
0
Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date when progressive disease or death was documented. It was based on tumor assessments made by the investigators according to the RECIST criteria. Participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants undergoing surgical resection with curative intent were censored at the date of surgery. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Query!
Timepoint [17]
0
0
From baseline until disease progression/recurrence, approximately 2 years 6 months
Query!
Secondary outcome [18]
0
0
Duration of Overall Response as Assessed by the Investigator According to RECIST: Superiority Analysis of Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone
Query!
Assessment method [18]
0
0
Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date when progressive disease or death was documented. It was based on tumor assessments made by the investigators according to the RECIST criteria. Participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants undergoing surgical resection with curative intent were censored at the date of surgery. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
Query!
Timepoint [18]
0
0
From baseline until disease progression/recurrence, approximately 2 years 6 months
Query!
Secondary outcome [19]
0
0
Duration of Complete Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
Query!
Assessment method [19]
0
0
For complete responders, the duration of complete response was measured from the time measurement criteria were first met for complete response until the date that progressive disease (or death) was documented. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Query!
Timepoint [19]
0
0
From baseline until disease progression/recurrence, approximately 2 years 6 months
Query!
Secondary outcome [20]
0
0
Duration of Complete Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
Query!
Assessment method [20]
0
0
For complete responders, the duration of complete response was measured from the time measurement criteria were first met for complete response until the date that progressive disease (or death) was documented. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
Query!
Timepoint [20]
0
0
From baseline until disease progression/recurrence, approximately 2 years 6 months
Query!
Eligibility
Key inclusion criteria
- Adult patients = 18 years of age.
- Metastatic colorectal cancer.
- = 1 target lesion.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Previous treatment with oxaliplatin or bevacizumab.
- Previous systemic chemotherapy or immunotherapy for advanced or metastatic disease.
- Progressive disease during or within 6 months of completion of previous adjuvant
therapy.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Factorial
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/07/2003
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2009
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
2035
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Adelaide
Query!
Recruitment hospital [2]
0
0
- Box Hill
Query!
Recruitment hospital [3]
0
0
- Brisbane
Query!
Recruitment hospital [4]
0
0
- Camperdown
Query!
Recruitment hospital [5]
0
0
- Fitzroy
Query!
Recruitment hospital [6]
0
0
- Footscray
Query!
Recruitment hospital [7]
0
0
- Kurralta Park
Query!
Recruitment hospital [8]
0
0
- Malvern
Query!
Recruitment hospital [9]
0
0
- Melbourne
Query!
Recruitment hospital [10]
0
0
- Perth
Query!
Recruitment hospital [11]
0
0
- Port Macquarie
Query!
Recruitment hospital [12]
0
0
- St. Leonards
Query!
Recruitment hospital [13]
0
0
- Sydney
Query!
Recruitment postcode(s) [1]
0
0
5011 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [3]
0
0
4101 - Brisbane
Query!
Recruitment postcode(s) [4]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [5]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [6]
0
0
3011 - Footscray
Query!
Recruitment postcode(s) [7]
0
0
5037 - Kurralta Park
Query!
Recruitment postcode(s) [8]
0
0
3144 - Malvern
Query!
Recruitment postcode(s) [9]
0
0
3002 - Melbourne
Query!
Recruitment postcode(s) [10]
0
0
3181 - Melbourne
Query!
Recruitment postcode(s) [11]
0
0
6000 - Perth
Query!
Recruitment postcode(s) [12]
0
0
2444 - Port Macquarie
Query!
Recruitment postcode(s) [13]
0
0
2065 - St. Leonards
Query!
Recruitment postcode(s) [14]
0
0
2031 - Sydney
Query!
Recruitment postcode(s) [15]
0
0
2139 - Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kentucky
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Louisiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maine
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Minnesota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Nevada
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New Jersey
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New Mexico
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New York
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
North Carolina
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
North Dakota
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Pennsylvania
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Rhode Island
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
South Carolina
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Tennessee
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Texas
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Vermont
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Virginia
Query!
Country [25]
0
0
Austria
Query!
State/province [25]
0
0
Wels
Query!
Country [26]
0
0
Austria
Query!
State/province [26]
0
0
Wien
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
JAÚ
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Rio de Janeiro
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
Sao Paulo
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Alberta
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
British Columbia
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Manitoba
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Nova Scotia
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Ontario
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Quebec
Query!
Country [36]
0
0
China
Query!
State/province [36]
0
0
Beijing
Query!
Country [37]
0
0
China
Query!
State/province [37]
0
0
Guangdong
Query!
Country [38]
0
0
China
Query!
State/province [38]
0
0
Guangzhou
Query!
Country [39]
0
0
China
Query!
State/province [39]
0
0
Jiangsu
Query!
Country [40]
0
0
China
Query!
State/province [40]
0
0
Jiangxi
Query!
Country [41]
0
0
China
Query!
State/province [41]
0
0
Shandong
Query!
Country [42]
0
0
China
Query!
State/province [42]
0
0
Shanghai
Query!
Country [43]
0
0
China
Query!
State/province [43]
0
0
Tianjin
Query!
Country [44]
0
0
China
Query!
State/province [44]
0
0
Wuhan
Query!
Country [45]
0
0
Czech Republic
Query!
State/province [45]
0
0
Brno
Query!
Country [46]
0
0
Czech Republic
Query!
State/province [46]
0
0
Chomutov
Query!
Country [47]
0
0
Czech Republic
Query!
State/province [47]
0
0
Hradec Kralove
Query!
Country [48]
0
0
Czech Republic
Query!
State/province [48]
0
0
Ostrava
Query!
Country [49]
0
0
Denmark
Query!
State/province [49]
0
0
Herlev
Query!
Country [50]
0
0
Denmark
Query!
State/province [50]
0
0
København
Query!
Country [51]
0
0
Denmark
Query!
State/province [51]
0
0
Odense
Query!
Country [52]
0
0
Finland
Query!
State/province [52]
0
0
Helsinki
Query!
Country [53]
0
0
Finland
Query!
State/province [53]
0
0
Tampere
Query!
Country [54]
0
0
Finland
Query!
State/province [54]
0
0
Turku
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Besancon
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Bobigny
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Boulogne-billancourt
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Brest
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Chambray Les Tours
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Colmar
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Dijon
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Grenoble
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Lyon
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Metz
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Nice
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Nimes
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Paris
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Pierre Benite
Query!
Country [69]
0
0
France
Query!
State/province [69]
0
0
Rouen
Query!
Country [70]
0
0
France
Query!
State/province [70]
0
0
Saint Herblain
Query!
Country [71]
0
0
France
Query!
State/province [71]
0
0
Toulouse
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Bochum
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Halle
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Hannover
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Herne
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Leipzig
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Mainz
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Mannheim
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Regensburg
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Stralsund
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Trier
Query!
Country [82]
0
0
Guatemala
Query!
State/province [82]
0
0
Guatemala City
Query!
Country [83]
0
0
Guatemala
Query!
State/province [83]
0
0
Guatemala
Query!
Country [84]
0
0
Hong Kong
Query!
State/province [84]
0
0
Hong Kong
Query!
Country [85]
0
0
Hungary
Query!
State/province [85]
0
0
Budapest
Query!
Country [86]
0
0
Hungary
Query!
State/province [86]
0
0
Gyor
Query!
Country [87]
0
0
Hungary
Query!
State/province [87]
0
0
Kecskemet
Query!
Country [88]
0
0
Ireland
Query!
State/province [88]
0
0
Cork
Query!
Country [89]
0
0
Ireland
Query!
State/province [89]
0
0
Dublin
Query!
Country [90]
0
0
Ireland
Query!
State/province [90]
0
0
Galway
Query!
Country [91]
0
0
Israel
Query!
State/province [91]
0
0
Haifa
Query!
Country [92]
0
0
Israel
Query!
State/province [92]
0
0
Jerusalem
Query!
Country [93]
0
0
Israel
Query!
State/province [93]
0
0
Petach Tikva
Query!
Country [94]
0
0
Israel
Query!
State/province [94]
0
0
Tel Aviv
Query!
Country [95]
0
0
Israel
Query!
State/province [95]
0
0
Zerifin
Query!
Country [96]
0
0
Italy
Query!
State/province [96]
0
0
Ancona
Query!
Country [97]
0
0
Italy
Query!
State/province [97]
0
0
Genova
Query!
Country [98]
0
0
Italy
Query!
State/province [98]
0
0
Modena
Query!
Country [99]
0
0
Italy
Query!
State/province [99]
0
0
Padova
Query!
Country [100]
0
0
Italy
Query!
State/province [100]
0
0
Parma
Query!
Country [101]
0
0
Italy
Query!
State/province [101]
0
0
Pavia
Query!
Country [102]
0
0
Italy
Query!
State/province [102]
0
0
Reggio Emilia
Query!
Country [103]
0
0
Italy
Query!
State/province [103]
0
0
Sassari
Query!
Country [104]
0
0
Korea, Republic of
Query!
State/province [104]
0
0
Seoul
Query!
Country [105]
0
0
Mexico
Query!
State/province [105]
0
0
Mexico City
Query!
Country [106]
0
0
New Zealand
Query!
State/province [106]
0
0
Christchurch
Query!
Country [107]
0
0
Norway
Query!
State/province [107]
0
0
Bergen
Query!
Country [108]
0
0
Norway
Query!
State/province [108]
0
0
Oslo
Query!
Country [109]
0
0
Norway
Query!
State/province [109]
0
0
Tromsø
Query!
Country [110]
0
0
Panama
Query!
State/province [110]
0
0
Panama City
Query!
Country [111]
0
0
Portugal
Query!
State/province [111]
0
0
Beja
Query!
Country [112]
0
0
Portugal
Query!
State/province [112]
0
0
Lisboa
Query!
Country [113]
0
0
Puerto Rico
Query!
State/province [113]
0
0
San Juan
Query!
Country [114]
0
0
Russian Federation
Query!
State/province [114]
0
0
Moscow
Query!
Country [115]
0
0
Russian Federation
Query!
State/province [115]
0
0
St Petersburg
Query!
Country [116]
0
0
South Africa
Query!
State/province [116]
0
0
Cape Town
Query!
Country [117]
0
0
South Africa
Query!
State/province [117]
0
0
Pretoria
Query!
Country [118]
0
0
South Africa
Query!
State/province [118]
0
0
Sandton
Query!
Country [119]
0
0
Spain
Query!
State/province [119]
0
0
Barcelona
Query!
Country [120]
0
0
Spain
Query!
State/province [120]
0
0
Córdoba
Query!
Country [121]
0
0
Spain
Query!
State/province [121]
0
0
Granada
Query!
Country [122]
0
0
Spain
Query!
State/province [122]
0
0
Leganes
Query!
Country [123]
0
0
Spain
Query!
State/province [123]
0
0
Madrid
Query!
Country [124]
0
0
Spain
Query!
State/province [124]
0
0
Málaga
Query!
Country [125]
0
0
Spain
Query!
State/province [125]
0
0
Santander
Query!
Country [126]
0
0
Spain
Query!
State/province [126]
0
0
Valencia
Query!
Country [127]
0
0
Spain
Query!
State/province [127]
0
0
Zaragoza
Query!
Country [128]
0
0
Sweden
Query!
State/province [128]
0
0
Gaevle
Query!
Country [129]
0
0
Sweden
Query!
State/province [129]
0
0
Karlstad
Query!
Country [130]
0
0
Sweden
Query!
State/province [130]
0
0
Stockholm
Query!
Country [131]
0
0
Sweden
Query!
State/province [131]
0
0
Uppsala
Query!
Country [132]
0
0
Sweden
Query!
State/province [132]
0
0
Västerås
Query!
Country [133]
0
0
Switzerland
Query!
State/province [133]
0
0
Bern
Query!
Country [134]
0
0
Switzerland
Query!
State/province [134]
0
0
Geneve
Query!
Country [135]
0
0
Taiwan
Query!
State/province [135]
0
0
Kueishan
Query!
Country [136]
0
0
Taiwan
Query!
State/province [136]
0
0
Taipei
Query!
Country [137]
0
0
Thailand
Query!
State/province [137]
0
0
Bangkok
Query!
Country [138]
0
0
Thailand
Query!
State/province [138]
0
0
Khon Kaen
Query!
Country [139]
0
0
Turkey
Query!
State/province [139]
0
0
Istanbul
Query!
Country [140]
0
0
Turkey
Query!
State/province [140]
0
0
Izmir
Query!
Country [141]
0
0
United Kingdom
Query!
State/province [141]
0
0
Aberdeen
Query!
Country [142]
0
0
United Kingdom
Query!
State/province [142]
0
0
Birmingham
Query!
Country [143]
0
0
United Kingdom
Query!
State/province [143]
0
0
Cardiff
Query!
Country [144]
0
0
United Kingdom
Query!
State/province [144]
0
0
Derby
Query!
Country [145]
0
0
United Kingdom
Query!
State/province [145]
0
0
Glasgow
Query!
Country [146]
0
0
United Kingdom
Query!
State/province [146]
0
0
Guildford
Query!
Country [147]
0
0
United Kingdom
Query!
State/province [147]
0
0
Hull
Query!
Country [148]
0
0
United Kingdom
Query!
State/province [148]
0
0
London
Query!
Country [149]
0
0
United Kingdom
Query!
State/province [149]
0
0
Maidstone
Query!
Country [150]
0
0
United Kingdom
Query!
State/province [150]
0
0
Newcastle Upon Tyne
Query!
Country [151]
0
0
United Kingdom
Query!
State/province [151]
0
0
Northwood
Query!
Country [152]
0
0
United Kingdom
Query!
State/province [152]
0
0
Nottingham
Query!
Country [153]
0
0
United Kingdom
Query!
State/province [153]
0
0
Plymouth
Query!
Country [154]
0
0
United Kingdom
Query!
State/province [154]
0
0
Salisbury
Query!
Country [155]
0
0
United Kingdom
Query!
State/province [155]
0
0
Southampton
Query!
Country [156]
0
0
United Kingdom
Query!
State/province [156]
0
0
Sutton
Query!
Country [157]
0
0
United Kingdom
Query!
State/province [157]
0
0
Taunton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This 4 arm study assessed the efficacy and safety of oral capecitabine (Xeloda) or
intravenous (iv) fluorouracil/leucovorin, in combination with iv oxaliplatin (Eloxatin) with
or without iv bevacizumab (Avastin), as a first-line treatment in patients with metastatic
colorectal cancer. Patients were randomized to receive 1) XELOX (Xeloda 1000 mg/m^2 orally
[po] twice a day [bid] on Days 1-15 + oxaliplatin in 3 week cycles), 2) FOLFOX-4 (oxaliplatin
+ leucovorin + fluorouracil [5-FU] in 2 week cycles), 3) XELOX + bevacizumab (7.5 mg iv on
Day 1 in 3 week cycles), or 4) FOLFOX-4 + bevacizumab (5 mg iv on Day 1 in 2 week cycles).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00069095
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00069095
Download to PDF